Syngen Biotech Co.,Ltd. (8279.TWO)
TWD 118.5
(-0.42%)
TWD 118.5
(-0.42%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 415.13 Million | 277.48 Million | 336.49 Million | 220.2 Million | - |
| Net Income | 333.8 Million | 396.41 Million | 295.49 Million | 263.37 Million | - |
| Depreciation & Amortization | 99.47 Million | 86.5 Million | 81.39 Million | 76.66 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | 8.64 Million |
| Change in working capital | 72.98 Million | -158.11 Million | -3.01 Million | -68.67 Million | - |
| Other non-cash items | 17.98 Million | 13.92 Million | 6.4 Million | 5.44 Million | - |
| Investing Cash Flow | -93.67 Million | -585.04 Million | -336.07 Million | -272.06 Million | - |
| Investments in PPE | -93.8 Million | -584.71 Million | -61.66 Million | -272.75 Million | - |
| Acquisitions | - | - | -273.84 Million | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | 124 Thousand | -334 Thousand | -1.03 Million | 693 Thousand | - |
| Financing Cash Flow | -200.53 Million | 238.75 Million | -108.87 Million | -43.99 Million | - |
| Debt repayment | -50 Million | -362 Million | - | -50 Million | - |
| Dividends payments | -135.5 Million | -108.4 Million | -94.85 Million | -81.3 Million | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | 478.52 Million |
| Other Financing Activities | 140 Thousand | 98 Thousand | - | -19 Thousand | 19 Thousand |
| Accounts receivables | 92.84 Million | - | - | - | - |
| Accounts payables | 20.49 Million | - | - | - | - |
| Inventory | 1.98 Million | -98.1 Million | -41.33 Million | -51.5 Million | - |
| Other working capital | -21.84 Million | - | - | - | - |
| Cash at beginning of period | 246.05 Million | 314.8 Million | 423.41 Million | 519.39 Million | - |
| Cash at end of period | 366.89 Million | 246.05 Million | 314.8 Million | 423.41 Million | - |
| Capital Expenditure | -93.8 Million | -584.71 Million | -61.66 Million | -272.75 Million | - |
| Effect of forex changes on cash | -78 Thousand | 64 Thousand | -164 Thousand | -123 Thousand | - |
| Net cash flow / Change in cash | 120.83 Million | -68.74 Million | -108.61 Million | -95.97 Million | - |
| Free Cash Flow | 321.32 Million | -307.22 Million | 274.82 Million | -52.55 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 63.37 Million | 71.13 Million | 333.8 Million | 71.74 Million | 84.74 Million | 87.76 Million |
| Depreciation & Amortization | 27.98 Million | 26.1 Million | 99.47 Million | 25.51 Million | 27.63 Million | 23.33 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -46.94 Million | -62.62 Million | 72.98 Million | 50.04 Million | 84.43 Million | -49.94 Million |
| Other non-cash items | -1.3 Million | 3.96 Million | 17.98 Million | 1.55 Million | 438 Thousand | 7.63 Million |
| Investing Cash Flow | -42.21 Million | -22.12 Million | -93.67 Million | -37.2 Million | -13.04 Million | -20.9 Million |
| Investments in PPE | -22.16 Million | -22.17 Million | -93.8 Million | -37.13 Million | -13.03 Million | -20.92 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -20 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -57 Thousand | 41 Thousand | 124 Thousand | -69 Thousand | -7000.00 | 19 Thousand |
| Financing Cash Flow | -48.45 Million | -17.98 Million | -200.53 Million | -53.61 Million | -89.5 Million | -3.76 Million |
| Debt repayment | -44.75 Million | -14.75 Million | -50 Million | -49.91 Million | -49.91 Million | - |
| Dividends payments | - | - | -135.5 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -3.7 Million | 45 Thousand | 140 Thousand | - | - | - |
| Accounts receivables | -87.79 Million | - | - | - | - | - |
| Accounts payables | -14.81 Million | - | - | - | - | - |
| Inventory | 11.92 Million | -5.82 Million | 1.98 Million | -10.34 Million | 46 Million | 2.48 Million |
| Other working capital | 29.3 Million | - | - | - | - | - |
| Cash at beginning of period | 370.27 Million | 366.89 Million | 246.05 Million | 320.97 Million | 222.32 Million | 274.43 Million |
| Cash at end of period | 270.59 Million | 370.27 Million | 366.89 Million | 366.89 Million | 320.97 Million | 222.32 Million |
| Capital Expenditure | -22.16 Million | -22.17 Million | -93.8 Million | -37.13 Million | -13.03 Million | -20.92 Million |
| Effect of forex changes on cash | 94 Thousand | 86 Thousand | -78 Thousand | -62 Thousand | 29 Thousand | -31 Thousand |
| Net cash flow / Change in cash | -99.68 Million | 3.38 Million | 120.83 Million | 45.92 Million | 98.64 Million | -52.1 Million |
| Free Cash Flow | -31.26 Million | 21.24 Million | 321.32 Million | 99.66 Million | 188.13 Million | -48.33 Million |
EMIL
BAYN
2393
NNCHY
BPAC3
002114